115 filings
Page 4 of 6
6-K
e9nwm kj95o
15 Mar 23
Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts
9:33pm
6-K
ash7yoynrw6b
14 Mar 23
Report of Foreign Private Issuer
9:11pm
EFFECT
vmwafi filacaz
14 Mar 23
Notice of effectiveness
12:15am
CORRESP
5n2ny7ihyk44mdllald
9 Mar 23
Correspondence with SEC
12:00am
UPLOAD
12fdt iy0vsttx0
8 Mar 23
Letter from SEC
12:00am
6-K
4pxc40
2 Mar 23
Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Commercial Potentiality
8:25pm
F-3
5pl2c7q1oj2f34fw4c1
2 Mar 23
Shelf registration (foreign)
3:05pm
6-K
8rrocl
27 Feb 23
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
9:35pm
6-K
9jjq uxyz
27 Feb 23
Report of Foreign Private Issuer
5:16pm
6-K
1d4g55 7o
26 Jan 23
Incannex Healthcare December 2022 Quarterly Activities Report and Appendix 4C Cash Flow Statement
8:32pm
6-K
0pgf9 o8jhyc
5 Dec 22
Report of Foreign Private Issuer
6:01am
6-K
invocw441zedrk
30 Nov 22
Report of Foreign Private Issuer
9:43pm
6-K
efwt86rwdu
28 Nov 22
Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases
8:19pm
6-K
1un5htgbe zci7p
25 Nov 22
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O
6:08am
6-K
66y7ck3c3 su2d
21 Nov 22
Addendum to Notice of Annual General Meeting
6:10am
6-K
aystszx9 3j26omnq41
17 Nov 22
Report of Foreign Private Issuer
6:01am
20-F
tkqydp4ezpb2safbe6n
28 Oct 22
Annual report (foreign)
6:31am
6-K
opiab9
21 Oct 22
Report of Foreign Private Issuer
6:08am
6-K
5lje8in1vr2v
11 Oct 22
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury
6:15am
6-K
oo19202u
7 Oct 22
Notice of date of Annual General Meeting
6:03am